esketamine - Search News

major depressive disorder, FDA and Esketamine

Times Now on MSN · 2h

What is Spravato, an FDA-approved First Standalone Esketamine-based Nasal Spray Monotherapy for Depression?

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and manufactured by Johnson & Johnson, this ketamine-based drug has been approved as a standalone treatment for major depressive disorder or MDD.

Popular Science · 12h

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

Hosted on MSN · 1d

FDA Expands Approval of Esketamine for Depression

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an inadequate response to at least two oral antidepressants, maker Johnson & Johnson announced on Tuesday.

FDA approves Spravato as monotherapy for adults with major depressive disorder

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

1hon MSN

TTUHSC Psychiatry chairman discusses newly approved antidepressant nasal spray

The FDA approved Spravato for those battling depression and has seen little to no improvement from two types of ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results